OPTN/SRTR 2011 Annual Data Report: lung.

Abstract	Lungs are allocated in part based on the Lung Allocation Score (LAS), which considers risk of death without transplant and posttransplant. Wait-list additions have been increasing steadily after an initial decline following LAS implementation. In 2011, the largest number of adult candidates were added to the waiting list in a single year since 1998; donation and transplant rates have been unable to keep pace with wait-list additions. Candidates aged 65 years or older have been added faster than candidates in other age groups. After an initial decline following LAS implementation, wait-list mortality increased to 15.7 per 100 wait-list years in 2011. Short- and long-term graft survival improved in 2011; 10-year graft failure fell to an all-time low. Since 1998, the number of new pediatric (aged 0-11 years) candidates added yearly to the waiting list has declined. In 2011, 19 pediatric lung transplants were performed, a transplant rate of 34.7 per 100 wait-list years. The percentage of patients hospitalized before transplant has not changed. Both graft and patient survival have continued to improve over the past decade. Posttransplant complications for pediatric lung transplant recipients, similar to complications for adult recipients, include hypertension, renal dysfunction, diabetes, bronchiolitis obliterans syndrome, and malignancy.
Authors	M Valapour, K Paulson, J M Smith, M I Hertz, M A Skeans, B M Heubner, L B Edwards, J J Snyder, A K Israni, B L Kasiske
Journal	American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons (Am J Transplant) Vol. 13 Suppl 1 Pg. 149-77 (Jan 2013) ISSN: 1600-6143 [Electronic] United States
PMID	23237700 (Publication Type: Journal Article)
Copyright	© Copyright 2012 The American Society of Transplantation and the American Society of Transplant Surgeons.
Chemical References	Immunosuppressive Agents
Topics	Humans Immunosuppressive Agents (administration & dosage) Lung Transplantation Tissue and Organ Procurement Treatment Outcome Waiting Lists

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!